# A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia

Study · id `cardio:ct-nct07799688` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07799688](<https://clinicaltrials.gov/study/NCT07799688>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07799688

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT07799688. Randomized; no masking; primary purpose treatment. Start 2026-09-11 (actual); primary completion 2028-10-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT07799688, source copy `cardio:ctgov-nct07799688-2026-10-09`, retrieved 2026-10-31)
- Started: 2026-09-11 (actual) (ClinicalTrials.gov record NCT07799688, source copy `cardio:ctgov-nct07799688-2026-10-09`, retrieved 2026-10-31)
- Primary completion: 2028-10-15 (anticipated) (ClinicalTrials.gov record NCT07799688, source copy `cardio:ctgov-nct07799688-2026-10-09`, retrieved 2026-10-31)
- Completion: 2028-10-15 (anticipated) (ClinicalTrials.gov record NCT07799688, source copy `cardio:ctgov-nct07799688-2026-10-09`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07799688, source copy `cardio:ctgov-nct07799688-2026-10-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07799688-2026-10-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia
- Condition: Hyperlipidemia
- Intervention (Drug): HRS-7249 Injection
- Intervention (Drug): HRS-7249 Injection
- Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. (`cardio:org-fujian-shengdi-pharmaceutical-co-ltd`)

## Provenance

Content hash: a8e379441306cf4c0341135345d4097a21f0731efb6b2ef4ca598580b147df74
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
